By Brian Marckx, CFANASDAQ:VIVEREAD THE FULL VIVE RESEARCH REPORTQ3 Results: Results Inline But FDA-Action vs. Competitors Could Create Short-Term Headwind. Long-Term Outlook Intact…Viveve (NASDAQ:VIVE) reported Q3 2018 financial results and provided a business update. Relative to the financials, both the top and bottom lines were a hair lower than...
By David Bautz, PhDNASDAQ:CERCREAD THE FULL CERC RESEARCH REPORTBusiness UpdateRare Pediatric Disease ProgramsOn October 31, 2018, Cerecor, Inc. (NASDAQ:CERC) announced the submission of three Orphan Drug Designation (ODD) requests for three of the development products acquired from the purchase of Ichorion Therapeutics, Inc. Each of them is being developed...
By John Vandermosten, CFAOTC:GOVXREAD THE FULL GOVX RESEARCH REPORTGeoVax Labs, Inc. (OTC:GOVX) filed their 3Q:18 10-Q and press release on November 8th providing an operational and financial update on the company’s performance. Several highlights were noted in the release, including the receipt of several grants from government entities, collaborations...
By John Vandermosten, CFANASDAQ:TENXREAD THE FULL TENX RESEARCH REPORTThird Quarter 2018 ReviewDuring the third quarter Tenax Therapeutics, Inc. (NASDAQ:TENX) continued to prepare its Phase II levosimendan trial for PH-HFpEF enrollment. Efforts in the areas of contracting, budgeting, scheduling, investigational review board approvals and site set up dominated the executive...
By John Vandermosten, CFANASDAQ:ATRSREAD THE FULL ATRS RESEARCH REPORTAntares Pharma, Inc. (NASDAQ:ATRS) reported third quarter results on November 6th posting revenue growth of 19% and achieving a quarterly sales record for the company. Earnings loss was limited to a penny. Highlights for the quarter and quarter to date include...
By John Vandermosten, CFANASDAQ:LPCNREAD THE FULL LPCN RESEARCH REPORT3Q:18 Operational and Financial ResultsLipocine (NASDAQ:LPCN) filed its 3Q:18 10-Q and posted its earnings release on November 7, 2018 reporting net loss per share of ($0.12). These results were better than our forecast due to lower R&D and G&A. Highlights for...
By John Vandermosten, CFANASDAQ:CORVREAD THE FULL CORV RESEARCH REPORT3Q:18 Operational and Financial ResultsCorrevio Pharma Corp. (NASDAQ:CORV) issued a press release reporting third quarter 2018 results on November 6, 2018 posting revenues of $7.0 million, a 16% increase over the prior year. Loss per share was ($0.20) as SG&A expenses...
By John Vandermosten, CFATSX:RVXREAD THE FULL TSX RESEARCH REPORTCapital Raise and ConferencesFollowing its first quarter fiscal year 2019 financial filings, Resverlogix Corp. (TSX:RVX) has continued to raise capital in preparation for its expected read out for the BETonMACE trial. Results are expected in the first half of calendar year...
By Brian Marckx, CFANYSE:VNRXREAD THE FULL VNRX RESEARCH REPORTQ3 Results / Operational and Business Update:VoltionRx (NYSE:VNRX) reported Q3 results and provided a business update. Relative to the financials, operating expenses of $4.5M were about 7% less than our $4.8M estimate and largely flat from the average during 1H’18. As...
By Lisa ThompsonNASDAQ:CSSEREAD THE FULL CSSE RESEARCH REPORTChicken Soup for the Soul Entertainment (NASDAQ:CSSE) reported Q3 numbers that showed remarkable progress over last year both for the quarter and the nine months. It has built a strong business and is even ahead of its own projections leading the company...